JP2005502679A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502679A5
JP2005502679A5 JP2003524594A JP2003524594A JP2005502679A5 JP 2005502679 A5 JP2005502679 A5 JP 2005502679A5 JP 2003524594 A JP2003524594 A JP 2003524594A JP 2003524594 A JP2003524594 A JP 2003524594A JP 2005502679 A5 JP2005502679 A5 JP 2005502679A5
Authority
JP
Japan
Prior art keywords
hyperalgesia
days
mechanical
measured
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003524594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/009662 external-priority patent/WO2003020287A2/en
Publication of JP2005502679A publication Critical patent/JP2005502679A/ja
Publication of JP2005502679A5 publication Critical patent/JP2005502679A5/ja
Pending legal-status Critical Current

Links

JP2003524594A 2001-08-30 2002-08-29 慢性疼痛の処置方法およびそのための組成物 Pending JP2005502679A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31589801P 2001-08-30 2001-08-30
PCT/EP2002/009662 WO2003020287A2 (en) 2001-08-30 2002-08-29 Methods for the treatment of chronic pain anc compositions therefor

Publications (2)

Publication Number Publication Date
JP2005502679A JP2005502679A (ja) 2005-01-27
JP2005502679A5 true JP2005502679A5 (https=) 2006-01-05

Family

ID=23226545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003524594A Pending JP2005502679A (ja) 2001-08-30 2002-08-29 慢性疼痛の処置方法およびそのための組成物

Country Status (4)

Country Link
US (2) US20030144234A1 (https=)
EP (1) EP1423128A2 (https=)
JP (1) JP2005502679A (https=)
WO (1) WO2003020287A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005601A (es) * 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
US20040147503A1 (en) * 2002-06-04 2004-07-29 Sheila Zipfeil Novel compounds and compositions as cathepsin inhibitors
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
PE20050068A1 (es) * 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
US20070037835A1 (en) * 2003-04-28 2007-02-15 Pamposh Ganju Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid
US7173051B2 (en) 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
GB0324542D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
EP1879923B1 (en) 2005-04-09 2015-05-27 Fusion Antibodies Limited Cathepsin s antibody
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2006125105A2 (en) * 2005-05-19 2006-11-23 Wyeth Methods and compositions for treating and diagnosing multiple sclerosis
JP2008545720A (ja) 2005-06-02 2008-12-18 メルク フロスト カナダ リミテツド カテプシン阻害剤としてのフルオロアルキルアミン誘導体
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP1991692A4 (en) * 2006-02-21 2009-07-22 Agency Science Tech & Res METHOD AND REAGENTS FOR THE TREATMENT OF LIVER FIBROSIS AND INFLAMMATION
CA2648947A1 (en) * 2006-04-10 2007-11-15 Fusion Antibodies Limited Therapy targeting cathepsin s
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090118274A1 (en) * 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090099157A1 (en) * 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2105742A1 (en) * 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C
BRPI0922283A2 (pt) 2008-12-19 2015-12-29 Medivir Uk Ltd inibidores da cistéina protease
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2293072A1 (en) * 2009-08-31 2011-03-09 Sanofi-Aventis Use of cathepsin H
EP2582660B1 (en) 2010-06-16 2015-07-22 Medivir UK Ltd New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
CA2251714A1 (en) * 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
EP1159273A1 (en) * 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2005502679A5 (https=)
Kawasaki et al. Effects of aging on RANKL and OPG levels in gingival crevicular fluid during orthodontic tooth movement
Bergström Tobacco smoking and risk for periodontal disease
Gonzalez et al. Gingival bleeding on probing: relationship to change in periodontal pocket depth and effect of sodium hypochlorite oral rinse
Do Amaral et al. A clinical follow‐up study of the periodontal conditions of RPD abutment and non‐abutment teeth
CY1107649T1 (el) Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος
JP2007228419A5 (https=)
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DE10346913A1 (de) Acylhydrazonderivate
Tomasini et al. Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases
Tan et al. Influence of maintenance care in periodontally susceptible and non‐susceptible subjects following implant therapy
Dani et al. The effectiveness of therapeutic ultrasound in patients with oral submucosal fibrosis
MX2007008136A (es) Metodo para invertir la resistencia multiple en celulas animales.
Wojda et al. Black bears with longer disuse (hibernation) periods have lower femoral osteon population density and greater mineralization and intracortical porosity
WO2004069173A3 (en) Methods for modulating an inflammatory response
FR2889062B1 (fr) Composition cosmetique comprenant un copolymere ampholyte
Tejera‐Vaquerizo et al. Thick melanoma: the problem continues
EP1351148A3 (en) Power profiling system and method for correlating runtime information
Pearlstein et al. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment
TW200501988A (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
EP1613585A4 (en) COMPOUNDS AND METHOD FOR USE IN THE TREATMENT OF NEOPLASMS AND CANCER BASED ON INHIBITORS OF ISOPRENYLCYSTEIN METHYLTRANSFERASE
Potdar et al. Evaluation of Salivary IL-8 and Calcium Levels in Postmenopausal Females with and without periodontitis—A Comparative Study
MXPA05008131A (es) Metodos para la modulacion de una respuesta inflamatoria.
RU2004103706A (ru) Способ оценки эффективности лечения и прогнозирования риска рекуррентности в течении депрессивных расстройств
RU2003100687A (ru) Способ оценки стрессустойчивости крупного рогатого скота